Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AVNS 
Avanos Medical Inc (AVNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: AVNS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.46% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 510.43M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 1.15 | 52 Weeks Range 9.30 - 23.68 | Updated Date 10/14/2025 |
52 Weeks Range 9.30 - 23.68 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -66.89% | Operating Margin (TTM) 1.43% |
Management Effectiveness
Return on Assets (TTM) 2.13% | Return on Equity (TTM) -46.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 572740109 | Price to Sales(TTM) 0.74 |
Enterprise Value 572740109 | Price to Sales(TTM) 0.74 | ||
Enterprise Value to Revenue 0.83 | Enterprise Value to EBITDA 17.17 | Shares Outstanding 46402481 | Shares Floating 45347289 |
Shares Outstanding 46402481 | Shares Floating 45347289 | ||
Percent Insiders 4.07 | Percent Institutions 97.56 |
Upturn AI SWOT
Avanos Medical Inc
Company Overview
History and Background
Avanos Medical, Inc. was formerly a part of Kimberly-Clark Corporation's healthcare business. It was spun off as an independent, publicly traded company in 2014. It focuses on chronic care and acute pain solutions.
Core Business Areas
- Chronic Care: This segment focuses on products and services that help patients manage chronic conditions, including digestive health and respiratory health. Key products include MIC-KEY feeding tubes.
- Acute Pain: This segment offers non-opioid pain relief solutions, primarily focused on regional anesthesia and intravenous (IV) analgesia. Key products include ON-Q pain relief system.
Leadership and Structure
Avanos Medical Inc.'s leadership team typically includes a CEO, CFO, and other key executives heading various functional areas. The organizational structure consists of functional departments like sales, marketing, R&D, operations, and finance.
Top Products and Market Share
Key Offerings
- ON-Q Pain Relief System: A non-opioid, post-operative pain management system that delivers local anesthetic directly to the surgical site. Competitors include Pacira BioSciences (EXPA) with EXPAREL, though ON-Q offers a different approach to local anesthetic delivery.
- MIC-KEY Feeding Tubes: Used for patients requiring long-term enteral feeding. Competitors include Medtronic (MDT) and Boston Scientific (BSX) who offer feeding access solutions.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory scrutiny, and increasing demand due to an aging population and rising healthcare expenditure. Growing demand for minimally invasive procedures and advancements in technology fuel growth.
Positioning
Avanos Medical Inc. is positioned as a provider of specialized medical devices with a focus on non-opioid pain relief and chronic care solutions. Its competitive advantage lies in its targeted product portfolio and expertise in niche markets.
Total Addressable Market (TAM)
TAM for acute pain management and enteral feeding is estimated to be in the billions of dollars annually. Avanos Medical Inc. holds a portion of the market and is seeking to expand its reach through product innovation and market penetration.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Focus on niche markets
- Strong brand recognition in certain product lines
- Established distribution network
Weaknesses
- Limited product diversification
- Dependence on key products
- Smaller scale compared to larger competitors
- Sensitivity to healthcare policy changes
Opportunities
- Expanding into new geographic markets
- Developing innovative products
- Acquiring complementary businesses
- Partnering with healthcare providers
Threats
- Increased competition
- Pricing pressure
- Regulatory changes
- Product liability risks
Competitors and Market Share
Key Competitors
- BSX
- MDT
- EXPA
- BDX
Competitive Landscape
Avanos Medical Inc. faces competition from larger, more diversified medical device companies. Its advantage lies in its focused product portfolio and expertise in niche markets. Disadvantages include smaller scale and limited resources.
Major Acquisitions
NeoMed
- Year: 2018
- Acquisition Price (USD millions): 30
- Strategic Rationale: Expanded enteral feeding solutions portfolio and provided access to neonatal and pediatric patient populations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require retrieving and analyzing the financial data for the company.
Future Projections: Future projections depend on analyst forecasts which are not available at this moment.
Recent Initiatives: Recent initiatives would include product launches, acquisitions, partnerships, and strategic investments.
Summary
Avanos Medical is a specialized medical device company with a focus on acute pain management and chronic care. While it holds a competitive position in niche markets, its growth is limited by its smaller size and dependence on key products. It is working to expand its market share through new product development. Avanos Medical Inc. should monitor regulatory changes and manage product liability risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avanos Medical Inc
Exchange NYSE | Headquaters Alpharetta, GA, United States | ||
IPO Launch date 2014-10-21 | CEO & Director Mr. David C. Pacitti M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2227 | Website https://avanos.com |
Full time employees 2227 | Website https://avanos.com | ||
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.